Clearance of amyloid-beta with bispecific antibody constructs bound to erythrocytes

Ronald P Taylor; Margaret A Lindorfer; John P Atkinson

doi:10.1002/trc2.12067

Clearance of amyloid-beta with bispecific antibody constructs bound to erythrocytes

Alzheimers Dement (N Y). 2020 Aug 27;6(1):e12067. doi: 10.1002/trc2.12067. eCollection 2020.

Authors

Ronald P Taylor¹, Margaret A Lindorfer¹, John P Atkinson²

Affiliations

¹ Department of Biochemistry and Molecular Genetics University of Virginia Charlottesville Virginia USA.
² Department of Medicine and Division of Rheumatology Washington University St. Louis Missouri USA.

Abstract

We propose use of bispecific monoclonal antibody (mAb) complexes bound to erythrocytes to redress the lack of efficacy of anti-amyloid beta mAbs in Alzheimer's disease treatment. Our paradigm leverages erythrocyte complement receptor 1 to promote rapid and quantitative removal of amyloid beta from the circulation, and its subsequent removal from the brain as well.

Keywords: Alzheimer's disease; amyloid beta; bispecific monoclonal antibodies; complement receptor 1; erythrocyte; human.

Grants and funding

R35 GM136352/GM/NIGMS NIH HHS/United States